Skip to main content
Top
Published in: Journal of Endocrinological Investigation 12/2023

02-06-2023 | Hypoparathyroidism | Original Article

PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism

Authors: A. Song, S. Chen, Y. Yang, Y. Jiang, Y. Jiang, M. Li, W. Xia, O. Wang, X. Xing

Published in: Journal of Endocrinological Investigation | Issue 12/2023

Login to get access

Abstract

Objective

Nonsurgical hypoparathyroidism (ns-HP) is a rare disease. There are few studies on Quality of Life (QoL) among patients with ns-HP. This study aimed to investigate the QoL among ns-HP patients with regular conventional treatment, and explore the influence factors affecting QoL among these Chinese ns-HP patients.

Methods

This is a cross-sectional study comparing 101 patients identified as ns-HP and 101 healthy controls. The questionnaires of Short Form 36 Health Survey questionnaire version 2(SF-36v2) were used to evaluate QoL.

Results

Scores of all eight subdomains of SF-36v2 and physical component scores (PCS), mental component scores (MCS) were significantly lower in the ns-HP group compared with the healthy controls. The indices of all subdomains of SF-36v2 between Q1 (the lowest quartile) and Q4 (the highest quartile) groups were compared, suggesting higher percentages of detectable parathyroid hormone (PTH) before treatment in Q4 group among all QoL indices except two subdomains (physical function and body pain).

Conclusion

Both mental and physical QoL were impaired in the ns-HP patients even with regular conventional treatment for hypocalcemia, which were more severe in cases with lower baseline PTH levels.
Literature
1.
go back to reference Underbjerg L, Sikjaer T, Mosekilde L et al (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744CrossRefPubMed Underbjerg L, Sikjaer T, Mosekilde L et al (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744CrossRefPubMed
2.
go back to reference Nakamura Y, Matsumoto T, Tamakoshi A et al (2000) Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol 10:29–33CrossRefPubMed Nakamura Y, Matsumoto T, Tamakoshi A et al (2000) Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol 10:29–33CrossRefPubMed
3.
go back to reference Halabe A, Arie R, Mimran D et al (1994) Hypoparathyroidism–a long-term follow-up experience with 1 alpha-vitamin D3 therapy. Clin Endocrinol (Oxf) 40:303–307CrossRefPubMed Halabe A, Arie R, Mimran D et al (1994) Hypoparathyroidism–a long-term follow-up experience with 1 alpha-vitamin D3 therapy. Clin Endocrinol (Oxf) 40:303–307CrossRefPubMed
5.
go back to reference Denko JD, Kaelbling R (1962) The psychiatric aspects of hypoparathyroidism. Acta Psychiatr Scand Suppl 38:1–70PubMed Denko JD, Kaelbling R (1962) The psychiatric aspects of hypoparathyroidism. Acta Psychiatr Scand Suppl 38:1–70PubMed
6.
go back to reference Arlt W, Fremerey C, Callies F et al (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215–222CrossRefPubMed Arlt W, Fremerey C, Callies F et al (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215–222CrossRefPubMed
7.
go back to reference Buttner M, Musholt TJ, Singer S (2017) Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58:14–20CrossRefPubMed Buttner M, Musholt TJ, Singer S (2017) Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58:14–20CrossRefPubMed
8.
go back to reference Palermo A, Santonati A, Tabacco G et al (2018) PTH (1–34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 103:271–280CrossRefPubMed Palermo A, Santonati A, Tabacco G et al (2018) PTH (1–34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 103:271–280CrossRefPubMed
9.
go back to reference Cusano NE, Rubin MR, McMahon DJ et al (2013) The effect of PTH (1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356–2361CrossRefPubMedPubMedCentral Cusano NE, Rubin MR, McMahon DJ et al (2013) The effect of PTH (1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356–2361CrossRefPubMedPubMedCentral
10.
go back to reference Cusano NE, Rubin MR, McMahon DJ et al (2014) PTH (1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694–3699CrossRefPubMedPubMedCentral Cusano NE, Rubin MR, McMahon DJ et al (2014) PTH (1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694–3699CrossRefPubMedPubMedCentral
11.
go back to reference Santonati A, Palermo A, Maddaloni E et al (2015) PTH (1–34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100:3590–3597CrossRefPubMed Santonati A, Palermo A, Maddaloni E et al (2015) PTH (1–34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100:3590–3597CrossRefPubMed
12.
go back to reference Tabacco G, Tay YD, Cusano NE et al (2019) Quality of Life in hypoparathyroidism improves with rhPTH (1–84) throughout 8 Years of therapy. J Clin Endocrinol Metab 104:2748–2756CrossRefPubMedPubMedCentral Tabacco G, Tay YD, Cusano NE et al (2019) Quality of Life in hypoparathyroidism improves with rhPTH (1–84) throughout 8 Years of therapy. J Clin Endocrinol Metab 104:2748–2756CrossRefPubMedPubMedCentral
13.
go back to reference Sikjaer T, Rolighed L, Hess A et al (2014) Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717–1726CrossRefPubMed Sikjaer T, Rolighed L, Hess A et al (2014) Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717–1726CrossRefPubMed
14.
go back to reference Roszko KL, Hu TY, Guthrie LC et al (2022) PTH 1–34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J Bone Miner Res 37:68–77CrossRefPubMed Roszko KL, Hu TY, Guthrie LC et al (2022) PTH 1–34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J Bone Miner Res 37:68–77CrossRefPubMed
15.
go back to reference Gittoes N, Rejnmark L, Ing SW et al (2021) The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord 21:232CrossRefPubMedPubMedCentral Gittoes N, Rejnmark L, Ing SW et al (2021) The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord 21:232CrossRefPubMedPubMedCentral
16.
go back to reference Kumanishi T, Washiyama K, Saito T et al (1986) Primary malignant lymphoma of the brain: an immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies. Acta Neuropathol 71:190–196CrossRefPubMed Kumanishi T, Washiyama K, Saito T et al (1986) Primary malignant lymphoma of the brain: an immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies. Acta Neuropathol 71:190–196CrossRefPubMed
17.
18.
go back to reference Sikjaer T, Moser E, Rolighed L et al (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440–1448CrossRefPubMed Sikjaer T, Moser E, Rolighed L et al (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440–1448CrossRefPubMed
19.
go back to reference Astor MC, Lovas K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in norway. J Clin Endocrinol Metab 101:3045–3053CrossRefPubMedPubMedCentral Astor MC, Lovas K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in norway. J Clin Endocrinol Metab 101:3045–3053CrossRefPubMedPubMedCentral
20.
go back to reference Underbjerg L, Sikjaer T, Rejnmark L (2018) Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) 88:838–847CrossRefPubMed Underbjerg L, Sikjaer T, Rejnmark L (2018) Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) 88:838–847CrossRefPubMed
21.
go back to reference Aggarwal S, Kailash S, Sagar R et al (2013) Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol 168:895–903CrossRefPubMed Aggarwal S, Kailash S, Sagar R et al (2013) Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol 168:895–903CrossRefPubMed
22.
go back to reference Sardella A, Bellone F, Morabito N et al (2021) The association between hypoparathyroidism and cognitive impairment: a systematic review. J Endocrinol Invest 44:905–919CrossRefPubMed Sardella A, Bellone F, Morabito N et al (2021) The association between hypoparathyroidism and cognitive impairment: a systematic review. J Endocrinol Invest 44:905–919CrossRefPubMed
23.
go back to reference Saponaro F, Alfi G, Cetani F et al (2022) Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 45:1909–1918CrossRefPubMedPubMedCentral Saponaro F, Alfi G, Cetani F et al (2022) Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 45:1909–1918CrossRefPubMedPubMedCentral
24.
go back to reference Bonavolontà V, Cianferotti L, Iolascon G et al (2022) Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. J Endocrinol Invest 45:1289–1295CrossRefPubMed Bonavolontà V, Cianferotti L, Iolascon G et al (2022) Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. J Endocrinol Invest 45:1289–1295CrossRefPubMed
25.
go back to reference Balabanov S, Tollner U, Richter HP et al (1984) Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol (Copenh) 106:227–233PubMed Balabanov S, Tollner U, Richter HP et al (1984) Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol (Copenh) 106:227–233PubMed
26.
go back to reference Usdin TB, Gruber C, Bonner TI (1995) Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 270:15455–15458CrossRefPubMed Usdin TB, Gruber C, Bonner TI (1995) Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 270:15455–15458CrossRefPubMed
27.
go back to reference Bago AG, Dimitrov E, Saunders R et al (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128–147CrossRefPubMed Bago AG, Dimitrov E, Saunders R et al (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128–147CrossRefPubMed
28.
go back to reference Vokes TJ, Mannstadt M, Levine MA et al (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722–731CrossRefPubMed Vokes TJ, Mannstadt M, Levine MA et al (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722–731CrossRefPubMed
29.
go back to reference Chomsky-Higgins KH, Rochefort HM, Seib CD et al (2018) Recombinant parathyroid hormone versus usual care: do the outcomes justify the cost? World J Surg 42:431–436CrossRefPubMed Chomsky-Higgins KH, Rochefort HM, Seib CD et al (2018) Recombinant parathyroid hormone versus usual care: do the outcomes justify the cost? World J Surg 42:431–436CrossRefPubMed
Metadata
Title
PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism
Authors
A. Song
S. Chen
Y. Yang
Y. Jiang
Y. Jiang
M. Li
W. Xia
O. Wang
X. Xing
Publication date
02-06-2023
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 12/2023
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-023-02100-9

Other articles of this Issue 12/2023

Journal of Endocrinological Investigation 12/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.